Narrow search
Showing 1 - 10 of 102
Cover Image
Collaboration, Stars, and the Changing Organization of Science : Evidence from Evolutionary Biology
Agrawal, Ajay - 2013
We report a puzzling pair of facts concerning the organization of science. The concentration of research output is declining at the department level but increasing at the individual level. For example, in evolutionary biology, over the period 1980 to 2000, the fraction of citation-weighted...
Persistent link: https://www.econbiz.de/10012459010
Cover Image
Crisis Innovation Policy from World War II to COVID-19
Gross, Daniel P.; Sampat, Bhaven N. - National Bureau of Economic Research - 2021
Innovation policy can be a crucial component of governments' responses to crises. Because speed is a paramount … objective, crisis innovation may also require different policy tools than innovation policy in non-crisis times, raising … distinct questions and tradeoffs. In this paper, we survey the U.S. policy response to two crises where innovation was crucial …
Persistent link: https://www.econbiz.de/10012585399
Cover Image
Tracing the Linkages Between Scientific Research and Energy Innovations : A Comparison of Clean and Dirty Technologies
Perrons, Robert K. - 2020
development of new energy technologies (Popp, 2017). Energy innovation tends to consist of a series of partially overlapping …
Persistent link: https://www.econbiz.de/10012481080
Cover Image
Expected Profits and The Scientific Novelty of Innovation
Dranove, David - 2020
Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …
Persistent link: https://www.econbiz.de/10012481677
Cover Image
The Economics of Crisis Innovation Policy : A Historical Perspective
Gross, Daniel P.; Sampat, Bhaven N. - National Bureau of Economic Research - 2021
-produced penicillin, antimalarials, and a flu vaccine. We draw on this episode to discuss the economics of crisis innovation. Since the …
Persistent link: https://www.econbiz.de/10012482553
Cover Image
Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003
Lichtenberg, Frank R. - 2008
Countries with larger increases in the share of cardiovascular drug doses that contained post-1990 or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate, controlling for the quantity of cardiovascular medications consumed per person, the use of...
Persistent link: https://www.econbiz.de/10012464639
Cover Image
Innovation, Diffusion, and Trade
Eaton, Jonathan - 2006
We explore the determinants of research specialization across countries and its consequences for relative wages. Using a dynamic Ricardian model we examine the effects of faster international technology diffusion and lower trade barriers on the incentive to innovate. In the absence of any...
Persistent link: https://www.econbiz.de/10012466280
Cover Image
Personal Bankruptcy Law and Innovation around the World
Cumming, Douglas J.; Morck, Randall; Rong, Zhao; Zhang, … - National Bureau of Economic Research - 2024
reforms also redistribute innovation across industries in closer alignment to its distribution in the U.S., which we take to … increasing value-added growth rates across all industries, and by larger margins in industries with more innovation potential …
Persistent link: https://www.econbiz.de/10015056150
Cover Image
Innovation Market Failures and the Design of New Climate Policy Instruments
Armitage, Sarah C.; Bakhtian, Noël; Jaffe, Adam B. - National Bureau of Economic Research - 2023
externalities but also by innovation market failures. This paper maps the economics literature on innovation market failures and …
Persistent link: https://www.econbiz.de/10014337854
Cover Image
Can Operation Warp Speed Serve as a Model for Accelerating Innovations Beyond COVID Vaccines?
D'Souza, Arielle; Hoyt, Kendall; Snyder, Christopher M.; … - National Bureau of Economic Research - 2024
Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...
Persistent link: https://www.econbiz.de/10015056157